Hyqvia start form?

See the DrugPatentWatch profile for Hyqvia

Who Manufactures Hyqvia and How is it Produced?

Hyqvia is a long-acting recombinant IgG1λ monoclonal antibody and recombinant human hyaluronidase-zuc5 for injection. It's manufactured by Bausch Health Companies Inc. (formerly known as Valeant Pharmaceuticals International).

According to [1] DrugPatentWatch.com, Hyqvia was initially developed by Baxalta, a biopharmaceutical company acquired by Shire in 2015. Since then, Shire was acquired by Takeda Pharmaceutical Company in 2018, and later, Takeda's biopharmaceuticals business was spun off as part of the separation of Shire's global pharmaceutical business, which is now a part of Bausch Health Companies Inc., as of 2020.

The manufacturing process for Hyqvia involves a recombinant DNA technology to produce a high concentration of the monoclonal antibody. The process includes fermentation, recovery, purification, formulation, and filling-and-finishing of the drug substance [1].

Difference between Hyqvia and Other Treatments?

Hyqvia is indicated for the treatment of primary immunodeficiency (PID) to provide additional immunoglobulin (Ig) replacement for adults and children. It's administered via subcutaneous injection every 4 weeks for 3 injections, and then every 28 days after the first three doses. It offers a dosing schedule that can provide sustained exposure to immunoglobulin, potentially improving patient compliance compared to other treatment options.

Comparison of Hyqvia with Keytruda (Pembrolizumab)

Keytruda and Hyqvia are vastly different in terms of their mechanism of action, indication, and formulation. While Keytruda is an anti-PD-1 therapy used in treating various types of cancer and other diseases, Hyqvia is a long-acting immunoglobulin replacement therapy. There's no direct comparison between these two drugs; however, both have their indications and benefits for patients with specific disease conditions.

Clinical Trials and Approval History

Hyqvia has undergone extensive clinical trials to assess its safety and efficacy. Multiple clinical trials have demonstrated the efficacy of Hyqvia in providing sustained exposure to immunoglobulin and maintaining Ig levels within the target range for up to 21 days after administration. It has received approval from the U.S. FDA and regulatory agencies in other countries, including the European Medicines Agency (EMA) [2].

References:

[1] DrugPatentWatch. (n.d.). Hyqvia. Retrieved from https://www.drugpatentwatch.com/drug/1457a/HYQVIA

[2] EMA. (2020). Hyqvia. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/hyqvia

[3] Bausch Health. (2022). HYQVIA. Retrieved from https://www.bauschhealth.com/brands/hyqvia